What is 7-OH? It’s short for 7-hydroxymitragynine, a naturally occurring kratom alkaloid that also appears in highly concentrated products. It has opioid-like activity, and federal regulators are weighing temporary controls on certain amounts and formulations.
Here’s the important distinction: as of October 27, 2026, the DEA has not yet issued its announced temporary scheduling order for 7-OH. The proposal has changed since summer, so some widely repeated details, especially the original 0.05% threshold, are out of date.
7-OH, in plain English
Kratom comes from Mitragyna speciosa, a tree native to Southeast Asia. Its leaves contain several alkaloids, including mitragynine, the most abundant, and 7-OH, which occurs naturally in much smaller amounts.
Mitragynine can also be converted into 7-OH in the body. In addition, concentrated 7-OH products may be made by processing plant-derived material or through chemical methods. The molecule is the same; its source and the amount present can be different.
Why does that distinction matter? A leaf containing a naturally occurring mix of alkaloids isn’t the same thing as a product designed to deliver a concentrated amount of one active compound. Concentration, composition, and product testing all matter.
For a broader introduction to the plant and its alkaloids, visit our Kratom guide.
Why is the DEA paying attention to 7-OH?
The DEA describes 7-OH as a psychoactive alkaloid with activity at opioid receptors. It has raised concerns about concentrated products, including unclear or inconsistent labeling, limited safety data, and the risks associated with opioid-like effects.
Those concerns aren’t the same as proof that every kratom product has the same risk profile. Traditional leaf, extracts, and highly concentrated 7-OH products can differ substantially in alkaloid content. “Kratom” on a label doesn’t tell you exactly what’s inside.
The FDA has also issued warning letters to companies marketing 7-OH products, stating that the agency has not approved 7-OH as a drug and that it has not authorized its use as a food additive. You can read the FDA’s announcement about those warning letters.
The federal timeline: what changed?
The scheduling story has a few turns. Here’s the short version, based on DEA and Federal Register notices available as of October 27, 2026:
- July 6, 2026: The DEA published a notice of intent to temporarily schedule 7-OH above a proposed threshold. The original proposal used a 0.05% threshold for certain materials and included a greater-than-1-milligram-per-article test for some processed or synthetic products.
- September 10, 2026: The extended deadline for comments on a related HHS request for information passed. That date was not a final scheduling date or the date 7-OH became federally controlled.
- August 26, 2026: A separate DEA order placed three related substances, mitragynine pseudoindoxyl, MGM-15, and MGM-16-in Schedule I. That order applies to those named compounds; it did not, by itself, place 7-OH in Schedule I.
- October 14, 2026: The DEA published a new notice of intent covering 7-OH and mitragynine pseudoindoxyl above a revised threshold. It withdrew the earlier 7-OH notice and replaced its proposed threshold.
The October 14 Federal Register notice says the DEA intends to issue a temporary order on or after November 13, 2026. A notice of intent is not the same as an order already in effect. As of October 27, the new order had not yet been issued.
What happened to the 0.05% threshold?
The 0.05% figure was part of the July proposal. It was later withdrawn, so don’t treat it as the current federal threshold.
The October proposal instead describes two tests for the substances it covers:
- Concentration: More than 1 milligram per gram for solid products, or more than 1 milligram per milliliter for liquid preparations.
- Alkaloid ratio: A ratio of mitragynine to 7-OH, or to the combined amount of 7-OH and mitragynine pseudoindoxyl, if both are present, of less than 100.
The notice describes control when the concentration is above the specified level or the ratio is below 100. These are proposed criteria, not a final rule already in force for 7-OH. Check the current official notice and any later DEA order before relying on a particular threshold.
Why isn’t plain kratom leaf automatically covered?
The DEA’s notices distinguish concentrated or processed products from botanical kratom that contains only trace amounts of 7-OH. Plain leaf naturally contains a mix of alkaloids, and the DEA’s October notice says the proposed threshold is intended to allow some products to remain outside Schedule I controls.
That is not a blanket guarantee that every leaf product is exempt, safe, or legal everywhere. Under the October proposal, the measured concentration and mitragynine-to-7-OH ratio matter. Testing and product composition matter, too.
In practical terms, plain leaf with naturally low 7-OH and a much higher mitragynine amount may fall below the proposed criteria. A product that is concentrated, altered, or formulated to raise 7-OH could be treated differently. A product’s label alone can’t confirm its alkaloid profile.
What does 7-OH safety information tell us?
There are no established, FDA-approved safe-use directions for 7-OH products. The DEA notice cites concerns including dependence, withdrawal, respiratory depression, and overdose, and it notes that the safety of concentrated products in humans is not established by controlled clinical trials.
If you’re evaluating a product, don’t let “natural,” “botanical,” or “lab-tested” do all the talking. Look for a current, product-specific certificate of analysis from an independent laboratory, and check whether it clearly identifies the tested product and reports relevant alkaloid amounts. A lab report is a quality-information tool, not proof that a product is safe or appropriate for you.
Avoid combining psychoactive substances, especially with alcohol, sedatives, or other drugs that can slow breathing. If you feel unusually drowsy, confused, faint, or have difficulty breathing after taking a substance, seek urgent medical help. For questions about personal health or medication interactions, talk with a qualified healthcare professional.
What about state law?
Federal proposals are only one piece of the map. State and local laws may restrict kratom, 7-OH, or particular product types more strictly, and those rules can change. Check the current law where you live before possessing, buying, or traveling with any product. This article is educational, not legal advice.
For the latest federal status, use the Federal Register notice as a starting point, and consult a qualified attorney for legal questions.
The takeaway
So, what is 7-OH? It’s a minor natural kratom alkaloid that can also be found in concentrated products, and the DEA is considering temporary Schedule I controls for certain amounts and formulations. The original 0.05% proposal was withdrawn; the October 2026 proposal uses different concentration and ratio criteria.
As of October 27, 2026, 7-OH itself had not yet been placed in Schedule I under the new notice. That could change after November 13, so check official updates rather than relying on an old headline.
Important notices
21+ only. Blaze Pages is intended for adults aged 21 or older, or the legal age of majority in your jurisdiction, whichever is higher.
Educational information, not medical or legal advice. Information about kratom and 7-OH has not been evaluated by the FDA as medical advice or as a recommendation for use. 7-OH is not an FDA-approved drug, and this article does not claim that it is safe or effective. Consult a qualified healthcare professional about health concerns; check local law or consult an attorney about legal questions.
Affiliate disclosure: This article contains no affiliate links and does not recommend or endorse a 7-OH product. Blaze Pages may publish sponsored or paid content elsewhere on the site; any such relationship should be disclosed with that content. Read our full disclaimer.
Suggested URL slug: 7-oh